Nephrology

Renal endpoints are meaningful but can be inherently noisy, burdensome, and costly due to the slow progression of CKD. This slow progression, combined with variable standards of care, necessitates a strategic trial design to address the logistical and recruitment barriers unique to renal patients. Built-in early signal checks can answer questions faster and provide for a more informed mode of action (MOA) and dose selection process. In addition, geographic diversity in the design yields genetic heterogeneity, stress testing the MOA, and informs a biologically real signal that is directionally consistent across regions.

Exploratory biomarkers do not replace clinical endpoints. They de-risk development by explaining biology, accelerating learning, and guiding critical decisions in CKD programs.

Misclassified disease is one of the biggest hidden barriers in renal clinical trials. Improving screening through biomarkers, genomics, centralized pathology, and phenotyping can enhance screening accuracy and dramatically increase trial success.

Using serum creatinine alone is a very limited marker of renal safety. Interpreting renal safety in nephrology requires differentiating between hemodynamic and structural renal effects, and adopting a multi-domain approach that includes physiology, pathophysiology, various eGFR assessments, and the use of Cystatin C.

Managing regulatory differences across global regulators is a core operational challenge in global nephrology trials. While the FDA, EMA, and NMPA align on many scientific standards, they differ in areas like endpoint acceptance, safety thresholds, and local trial requirements. The key is designing a program that includes early regulatory consultation, harmonizes endpoints early, meets the strictest shared expectations, and allows for region-specific adaptations.

Retention in fragile CKD and rare disease trials improves when protocols are low-burden, flexible, and patient-centered, and when they are supported by an understanding of site/PI challenges, strong site engagement, remote monitoring tools, and patient education programs.

Ideally, before Phase II. Early involvement helps determine whether the disease biology is complement- or immune-mediated, or primarily tubular, to interpret early efficacy and renal safety signals. Engaging nephrology leaders from the outset also improves site selection, patient recruitment strategies, and biomarker integration, ultimately increasing the likelihood that clinical trials generate meaningful and approvable evidence for kidney therapies.

Sites appreciate well-written, well-supported protocols with strong standard operating procedures (SOPs). Sponsors and CROs should avoid overly complex protocols as renal sites are typically overburdened, which can impact rigor. Trigger-based monitoring can help detect clinically meaningful changes early—such as Acute Kidney Injury, disease flares, or sudden increases in renal injury biomarkers—and guide rapid intervention rather than relying only on scheduled site visits. This approach can also support patient safety by allowing earlier detection of drug-related toxicity or disease progression and supporting more responsive trial management.